Corbus Pharmaceuticals Holdings Inc Stock

$17.95

2.75% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

US21833P1030

Symbol

CRBP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Corbus Pharmaceuticals Holdings Inc Stock price

$17.95

-123.35 87.30% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

+0.48 2.75%

ISIN

US21833P1030

Symbol

CRBP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$218.62m
Enterprise Value	$62.58m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.45
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-46.22m
Free Cash Flow (TTM) Free Cash Flow	$-36.86m
Cash position	$159.65m
EPS (TTM) EPS	$-4.70
P/E forward	negative
Short interest	23.79%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Corbus Pharmaceuticals Holdings Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

8x Buy

100%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Corbus Pharmaceuticals Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.70 0.70	33% 33% -
Gross Profit	-0.70 -0.70	33% 33% -
- Selling and Administrative Expenses	14 14	9% 9% -
- Research and Development Expense	30 30	0% 0% -
EBITDA	-46 -46	2% 2% -
- Depreciation and Amortization	0.70 0.70	33% 33% -
EBIT (Operating Income) EBIT	-46 -46	1% 1% -
Net Profit	-39 -39	18% 18% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Corbus Pharmaceuticals Holdings Inc Stock News

Neutral

Seeking Alpha

●

15 days ago

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liq...

Neutral

GlobeNewsWire

●

28 days ago

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

NORWOOD, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Guggenheim Securities Healthcare Innovation Conference to be held November 11-13, 2024 in Boston, MA.

Neutral

GlobeNewsWire

●

about one month ago

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study (NCT06265727) i...

More Corbus Pharmaceuticals Holdings Inc News

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Head office	United States
CEO	Yuval Cohen
Employees	19
Founded	2009
Website	www.corbuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now